Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Petechiae and non-blanching rash

Paediatrics and child health · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Unwell child with non-blanching rash

Toxic appearance, shock, altered consciousness, severe limb pain, meningism or rapidly spreading petechiae or purpura can indicate meningococcal disease or another invasive bacterial infection.

Action: Use ABCDE, call senior paediatric and critical-care support, obtain cultures and blood tests only if this does not delay care, give prompt guideline-directed parenteral ceftriaxone or cefotaxime and resuscitate. Arrange urgent transfer and do not wait for lumbar puncture, imaging or rash progression.

Synopsis

Treat a non-blanching rash as a time-critical sign when the child is unwell, while using distribution, palpability, platelet and coagulation patterns and renal or systemic findings to distinguish meningococcal disease, ITP, IgA vasculitis, malignancy and mechanical petechiae.

  • Petechiae are pinpoint non-blanching lesions; purpura are larger. Press with a clear glass only as an aid—good lighting, skin tone and the child's physiology matter more than a single bedside trick.
  • Any child with a non-blanching rash and toxic appearance, altered consciousness, shock, severe limb pain, rapidly spreading purpura or meningism needs immediate sepsis and meningococcal management.
  • Use ABCDE, obtain vascular access and blood cultures when this does not delay care, give guideline-directed parenteral ceftriaxone or cefotaxime and arrange urgent paediatric transfer; do not wait for lumbar puncture.
  • Meningococcal disease may begin with fever, leg pain, cold hands or feet and pallor before obvious purpura, and absence of neck stiffness does not reassure a young child.
  • A well child with isolated thrombocytopenia, petechiae and bruising but no hepatosplenomegaly, bone pain or lymphadenopathy may have immune thrombocytopenia; bleeding phenotype matters more than platelet count alone.
  • Palpable purpura over legs and buttocks with abdominal pain, arthralgia or renal findings suggests IgA vasculitis; measure blood pressure and urinalysis even when the child looks well.
  • Petechiae confined above the nipple line after forceful coughing or vomiting can be mechanical, but only after a full history and examination excludes systemic illness and safeguarding concern.
  • Pallor, fever, weight loss, night sweats, bone pain, hepatosplenomegaly, lymphadenopathy or abnormalities in more than one blood-cell line raises leukaemia or marrow failure.
  • Check full blood count and film, coagulation, renal and liver profile, CRP and cultures according to illness; use lumbar puncture only after stabilisation and contraindication assessment.
  • Safeguarding remains part of the differential when petechiae, bruises or patterned lesions are unexplained, protected-site or inconsistent with development; infection and inflicted injury can coexist.

Key red flags

Rapidly spreading purpura with shock, drowsiness or severe limb pain is meningococcal disease until urgently treated.

Cold extremities, prolonged refill and tachycardia may precede hypotension and visible purpura in a septic child.

Mucosal bleeding, haematuria, gastrointestinal bleeding or neurological symptoms indicate bleeding beyond the skin.

Pallor, persistent fever, night sweats, bone pain, nodes or organomegaly suggests leukaemia or marrow failure.

Severe abdominal or testicular pain with IgA vasculitis can indicate bowel or scrotal complication.

Hypertension, proteinuria or impaired renal function after palpable purpura needs urgent nephrology-aware review.

Unexplained petechiae on protected sites or an inconsistent account requires a safeguarding response without delaying medical care.

Rapid purpuric deterioration

Spreading non-blanching lesions with altered consciousness, shock or severe pain requires immediate sepsis treatment.

Investigation priorities

01
First-line physiological and full-skin assessmentFirst stepFirst line

Determine immediate sepsis risk and document distribution, spread, palpability, bleeding and safeguarding clues.

Management branches

Unwell childTreat invasive disease immediately

Non-blanching rash accompanies abnormal physiology, altered consciousness, severe pain, meningism or rapid spread.

  1. Use ABCDE, obtain IV or IO access and call senior paediatric and critical-care teams while documenting rash progression.
  2. Take cultures and essential bloods if immediate, give ceftriaxone or cefotaxime under the current pathway and resuscitate perfusion.
  3. Transfer urgently, defer unsafe lumbar puncture and monitor coagulation, limbs and organ function in high-dependency care.

Key medicines

Ceftriaxone or cefotaximeGive the current age- and weight-specific parenteral dose immediately under NICE and local paediatric meningococcal guidance; use cefotaxime when ceftriaxone is contraindicated, including relevant neonatal calcium considerations.Do not delay for lumbar puncture or imaging, document allergy and prior antibiotic, and follow neonatal, renal, meningitis and resistance-specific local advice.
Pre-hospital benzylpenicillinWhen meningococcal disease is strongly suspected outside hospital, give the current age-based emergency dose if local guidance recommends it and administration will not delay ambulance transfer.Immediate transfer and ABCDE take priority; follow severe allergy guidance and tell the receiving team the exact dose and time.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG240 meningitis and meningococcal diseaseRecognition, immediate antibiotics, transfer, investigations, lumbar-puncture safety and acute complications.
  • NICE NG254 managing suspected sepsisCurrent under-16 risk response, investigation, time-critical antimicrobial treatment, fluids, monitoring and escalation.
  • NICE NG12 suspected cancerUrgent referral features for childhood leukaemia and bone or soft-tissue malignancy.
  • UK Kidney Association IgA vasculitis guidelineUK paediatric IgA vasculitis diagnosis, baseline blood pressure, urine screening, complications and follow-up.
  • BNF for ChildrenCurrent child ceftriaxone, cefotaxime, benzylpenicillin and bleeding-treatment regimens and cautions.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewUnited Kingdom
Jurisdiction